Clinical Trial

A Multi-centered，Randomized，Double-blind，Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR-1703 in Eosinophilic Asthma

Name: A Multi-centered，Randomized，Double-blind，Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR-1703 in Eosinophilic Asthma — clinical trial record (NCT06653322)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The purpose of this study is to evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients with Eosinophil Phenotype

Protocol Amendment History 1 change

critical Enrollment closed, study ongoing 2026-08-11

Trial Details

NCT Number	NCT06653322
Lead Sponsor	Guangdong Hengrui Pharmaceutical Co., Ltd
Conditions	Asthma With Eosinophilic Phenotype
Enrollment	401 participants
Start Date	2024-11-21
Primary Completion	2027-09 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-08-10